DrugId:  1
1. Name:  XP12B
2. Groups:  Investigational
3. Description:  XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.
4. Indication:  Investigated for use/treatment in menstrual disorders.
DrugId:  2
1. Name:  Phylloquinone
2. Groups:  Approved, Investigational
3. Description:  Phylloquinone is often called vitamin K1. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants. Phylloquinone is also an antidote for coumatetralyl. Vitamin K is needed for the posttranslational modification of certain proteins, mostly required for blood coagulation.
4. Indication:  For the treatment of haemorrhagic conditions in infants, antidote for coumarin anticoagulants in hypoprothrombinaemia.
